Barriers to inhaled gene therapy of obstructive lung diseases: A review
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Knowledge of genetic origins of obstructive lung diseases has made inhaled gene therapy an attractive alternative to the current standards of care that are limited to managing disease symptoms. Initial lung gene therapy clinical trials occurred in the early 1990s following the discovery of the genetic defect responsible for cystic fibrosis (CF), a monogenic disorder. However, despite over two decades of intensive effort, gene therapy has yet to help patients with CF or any other obstructive lung disease. The slow progress is due in part to poor understanding of the biological barriers to inhaled gene therapy. Encouragingly, clinical trials have shown that inhaled gene therapy with various viral vectors and non-viral gene vectors is well tolerated by patients, and continued research has provided valuable lessons and resources that may lead to future success of this therapeutic strategy. In this review, we first introduce representative obstructive lung diseases and examine limitations of currently available therapeutic options. We then review key components for successful execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers and strategies to overcome them, and advances in preclinical disease models with which the most promising systems may be identified for human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“Lipid- and Polymer-based Facile chemical modification [137] Minimal constraint in packaging capacity [151, 184] Large-scale production [186] Variety of FDA-approved drug delivery formulations [187] Controlled release is achievable [139] Cytotoxicity [153, 173] No intrinsic tropism [139] (Lipid) Occasional stability is…”
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Self-citationNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 2×
“Lipid- and Polymer-based Facile chemical modification [137] Minimal constraint in packaging capacity [151, 184] Large-scale production [186] Variety of FDA-approved drug delivery formulations [187] Controlled release is achievable [139] Cytotoxicity [153, 173] No intrinsic tropism [139] (Lipid) Occasional stability is…”
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 2×
“Another limitation of retroviral vectors is their inability to infect non-dividing cells [121], which limits their use for inhaled gene therapy applications given the slow turnover rate of airway epithelium [7].”
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366 · cited 1×
“Lipid- and Polymer-based Facile chemical modification [137] Minimal constraint in packaging capacity [151, 184] Large-scale production [186] Variety of FDA-approved drug delivery formulations [187] Controlled release is achievable [139] Cytotoxicity [153, 173] No intrinsic tropism [139] (Lipid) Occasional stability is…”
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195 · cited 1×
“Ivacaftor demonstrated significant improvements in lung function of CF patients [24, 25].”
Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications
Sato, T., & Clevers, H. (2013) · Science · doi:10.1126/science.1234852 · Cited by 1,170 · cited 1×
“Primary human organoids differentiated from patient-derived stem cells are also an attractive in vitro model for high-throughput screening [434].”
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088 · cited 2×
“Another drug, lumacaftor (VX-809), showed promising in vitro correction of the most prevalent CFTR mutation, ΔF508, which represents ~70% of CF patients [26].”
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999 · cited 1×
“Specifically for CF, the organoid’s degree of swelling in response to the treatment with a well-documented CFTR activator, forskolin, was found to correlate with CFTR function, providing a means to assess CFTR activity and/or correction [435].”
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“AAV is a non-enveloped, icosahedral, non-replicating capsid virus with a diameter of roughly 25 nm [97].”
Systemic oxidative stress in asthma, COPD, and smokers
Rahman, I., Morrison, D., Donaldson, K., & MacNee, W. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.4.8887607 · Cited by 774 · cited 1×
“It is conceivable that other obstructive lung diseases characterized by elevated oxidative stress, including COPD and asthma [205], may share this feature.”
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 2×
“Given the promising preclinical and clinical results, AAV has been the most extensively engineered viral vector to date using both directed evolution and rational design approaches [296-298].”
Parameters influencing the stealthiness of colloidal drug delivery systems
Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.039 · Cited by 740
Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Shak, S., Capon, D. J., Hellmiss, R., Marsters, S. A., & Baker, C. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9188 · Cited by 707
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“A significant fraction of CF patients harbor active antibodies against AAV2 (32%) and AdV (55%) [221], which may further enhance adhesive entrapment in CF mucus and/or inactivate their capacity to transduce target cells.”
Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling
Johnson, J. R., Wiley, R. E., Fattouh, R., Swirski, F. K., Gajewska, B. U., Coyle, A. J., Gutierrez-Ramos, J.-C., Ellis, R., Inman, M. D., & Jordana, M. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1094oc · Cited by 435
Effective mucus clearance is essential for respiratory health
Randell, S. H., & Boucher, R. C. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0082sf · Cited by 335 · cited 1×
“Despite being relatively less explored, airway dehydration appears to be a common concern for other obstructive lung diseases, including COPD [242] and asthma [243].”
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · cited 1×
“This is achieved by either packaging overlapping genomes, which reconstruct the full length gene through homologous recombination after viral entry, or by evenly splitting the genome between two vector genomes that then combine after infection through trans-splicing via heterodimerization [117].”
Efficient gene transfer to airway epithelium using recombinant Sendai virus
Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., et al. (2000) · Nature Biotechnology · doi:10.1038/79463 · Cited by 244 · cited 1×
“Incorporating components from the capsid of other respiratory viruses, such as bocavirus [112], baculovirus [9] and sendai virus (SeV) [9, 130, 306], is also a common strategy to introduce lung tropism.”
Alveolar Macrophage in the Driver's Seat
Lambrecht, B. N. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.008 · Cited by 242 · cited 1×
“Alveolar macrophages—Alveolar macrophages are phagocytes residing in the airspace that play a critical role in homeostasis, host defense and tissue remodeling [254].”
Submucosal glands and airway defense
Wine, J. J., & Joo, N. S. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.2306015 · Cited by 223 · cited 1×
“Of note, submucosal glands are the primary source of the airway mucus secretion in the human lungs [200] and plays critical roles in innate immunity by secreting antimicrobials [342].”
Mastorakos, P., da Silva, A. L., Chisholm, J., Song, E., Choi, W. K., Boyle, M. P., Morales, M. M., Hanes, J., & Suk, J. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502281112 · Cited by 210
Self-citationGene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178 · cited 1×
“The recent approval of adeno-associated virus (AAV) type 1 as a vector for gene therapy in patients with lipoprotein lipase deficiency in Europe (GlyberaTM) [80] has provided renewed optimism in virus-mediated gene therapy.”
Fink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 2×
“In addition, CK30PEG10K was shown to effectively complex plasmid DNA with sizes up to 20 kb [184] and to transfect post-mitotic cells [180].”
Halbert, C. L., Allen, J. M., & Miller, A. D. (2002) · Nature Biotechnology · doi:10.1038/nbt0702-697 · Cited by 121 · cited 2×
“resulted in production of the encoded protein in the mouse lung to a level comparable to what achieved by a single AAV6 carrying the intact gene [118].”
Yan, Z., Zak, R., Zhang, Y., & Engelhardt, J. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.364-379.2005 · Cited by 107 · cited 1×
“ITR is a key element required for packaging therapeutic nucleic acid payloads into the AAV capsid [111].”
Suk, J. S., Boylan, N. J., Trehan, K., Tang, B. C., Schneider, C. S., Lin, J.-M. G., Boyle, M. P., Zeitlin, P. L., Lai, S. K., Cooper, M. J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.160 · Cited by 94 · cited 6×
“The promise in the preclinical studies resulted in its evaluation in 12 CF patients who received CK30PEG10K complexed with human CFTR-encoding plasmid DNA administered intranasally [159].”
InfluentialSelf-citationKoirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt013 · Cited by 75
da Silva, A. L., Martini, S. V., Abreu, S. C., Samary, C. D. S., Diaz, B. L., Fernezlian, S., de Sá, V. K., Capelozzi, V. L., Boylan, N. J., Goya, R. G., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.02.010 · Cited by 61
Self-citation
Cited by
Schneider, C. S., Xu, Q., Boylan, N. J., Chisholm, J., Tang, B. C., Schuster, B. S., Henning, A., Ensign, L. M., Lee, E., Adstamongkonkul, P., et al. (2017) · Science Advances · doi:10.1126/sciadv.1601556 · Cited by 311
Self-citationProtein nanocages that penetrate airway mucus and tumor tissue
Huang, X., Chisholm, J., Zhuang, J., Xiao, Y., Duncan, G., Chen, X., Suk, J. S., & Hanes, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705407114 · Cited by 131
“One of the primary barriers to effective inhalation of therapeutics to the lung airways is the protective mucus gel layer lining the airway epithelium (15, 16).”
BackgroundSelf-citationGuan, S., Munder, A., Hedtfeld, S., Braubach, P., Glage, S., Zhang, L., Lienenklaus, S., Schultze, A., Hasenpusch, G., Garrels, W., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0358-x · Cited by 130
Zhu, J., Guo, M., Cui, Y., Meng, Y., Ding, J., Zeng, W., & Zhou, W. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c23069 · Cited by 46
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Metadata
- Authors
- Kim, N., Duncan, G. A., Hanes, J., & Suk, J. S.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 240
- Pages
- 465-488
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2397508962
- Cited by
- 118
- References
- 31
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.